N/A
N=325
Substance Use Treatment and Recovery Team
Opioid-use Disorder · Opioid-Related Disorders
Bottom Line
View on ClinicalTrials.gov: NCT05086796 ↗Enrolled (actual)
325
Serious AEs
2.2%
Results posted
Jan 2025
Primary outcome: Primary: In-hospital Initiation of MOUD Therapy — 94; 43 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Substance Use Treatment and Recovery Team (START) (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Cedars-Sinai Medical Center
- Primary completion
- Dec 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY In-hospital Initiation of MOUD Therapy |
94; 43 | — |
| PRIMARY Linkage to Follow-up OUD Care |
90; 50 | — |
| SECONDARY OUD-specific Discharge Plan |
81; 44 | — |
| SECONDARY Any Post-discharge MOUD Utilization |
65; 32 | — |
| SECONDARY Post-discharge Outpatient Medical Care |
42; 19 | — |
| SECONDARY Past 30-day Number of Days With Any Opioid Use |
0.0; 0.0 | — |
Summary
This study is a multi-site, randomized pragmatic trial being conducted at three diverse sites. The study, called the Substance Use Treatment and Recovery Team (START), will evaluate whether a collaborative care team increases the use of two interventions-medication for opioid use disorder (MOUD), and opioid use disorder (OUD) focused discharge planning-among hospitalized patients with OUD, and improves linkage to follow-up care relative to usual care. The START consists of an addiction medicine specialist and a care manager who will use evidence-based tools to decrease barriers to MOUD and engage patients with post-discharge OUD care. A total of 414 patients will be randomized from Cedars-Sinai Medical Center in Los Angeles, the University of New Mexico Hospital in Albuquerque, and Baystate Health in Springfield, Massachusetts to receive either START or usual care, stratifying by prior MOUD exposure and site.
Eligibility Criteria
Inclusion Criteria
- Admitted to an inpatient bed at Cedars-Sinai Medical Center (CSMC),University of New Mexico Hospital (UNM), or Baystate Health (BH)
- Age 18 and older
- Have a probable OUD diagnosis, defined by scores of > 3 on the opioid section of the Alcohol, Smoking, and Substance Involvement Screening test (ASSIST)
- Speaks English or Spanish as primary language
- Willing to participate in follow-up calls and interview by telephone and able to provide contact information for follow-up calls
- Able to provide informed consent
Exclusion Criteria
- Currently receiving FDA-approved medication treatment for an opioid use disorder
- < 6 months life expectancy
Data sourced from ClinicalTrials.gov (NCT05086796). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.